Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Voltage-gated ion channel" patented technology

Voltage-gated ion channels are a class of transmembrane proteins that form ion channels that are activated by changes in the electrical membrane potential near the channel. The membrane potential alters the conformation of the channel proteins, regulating their opening and closing. Cell membranes are generally impermeable to ions, thus they must diffuse through the membrane through transmembrane protein channels. They have a crucial role in excitable cells such as neuronal and muscle tissues, allowing a rapid and co-ordinated depolarization in response to triggering voltage change. Found along the axon and at the synapse, voltage-gated ion channels directionally propagate electrical signals. Voltage-gated ion-channels are usually ion-specific, and channels specific to sodium (Na⁺), potassium (K⁺), calcium (Ca²⁺), and chloride (Cl⁻) ions have been identified. The opening and closing of the channels are triggered by changing ion concentration, and hence charge gradient, between the sides of the cell membrane.

Compositions useful as inhibitors of voltage-gated ion channels

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Owner:VERTEX PHARMA INC

Methods, compositions, and kits for treating pain and pruritis

The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and / or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels, wherein the second compound is capable of entering nociceptors or pruriceptors through the channel-forming receptor when the receptor is activated. The invention also features a quarternary amine derivative or other permanently or transiently charged derivative of a compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels.
Owner:THE GENERAL HOSPITAL CORP +1

Pyrimidines useful as modulators of voltage-gated ion channels

The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Owner:VERTEX PHARMA INC

Bicyclic derivatives as modulators of voltage gated ion channels

Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.
Owner:VERTEX PHARMA INC

Biphenyl derivatives as modulators of voltage gated ion channels

Biphenyl derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.
Owner:VERTEX PHARMA INC

Systems and methods of voltage-gated ion channel assays

Systems and methods are provided for optically measuring ion concentrations in biological samples. The systems and methods employ polymer-based optical ion sensors that include ion-selective ionophores and a pH sensitive chromionophore. Electrodes are providing for electrically stimulating the biological samples.
Owner:CHARLES STARK DRAPER LABORATORY

B-Superfamily conotoxins

The present invention is directed to β-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the β-superfamily conotoxin peptides and encoding β-superfamily conotoxin propeptides, as well as the β-superfamily conotoxin propeptides.
Owner:UNIV OF UTAH RES FOUND +1

Cone snail peptides

The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and / or receptors. The invention is further directed to nucleic acid sequences encoding the conotoxin peptides and encoding propeptides, as well as the propeptides.
Owner:THE UNIV OF UTAH +1

Quinazolines useful as modulators of voltage gated ion channels

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Owner:VERTEX PHARMA INC

Pyrimidines useful as modulators of voltage-gated ion channels

The present invention relates to compounds of formula (I) useful as inhibitors of voltage-gated ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Owner:VERTEX PHARMA INC

Methods, compositions, and kits for treating pain and pruritis

The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and / or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels, wherein the second compound is capable of entering nociceptors or pruriceptors through the channel-forming receptor when the receptor is activated. The invention also features a quarternary amine derivative or other permanently or transiently charged derivative of a compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1

Schizophrenia-related voltage-gated ion channel gene and protein

InactiveUS20080184381A1Altered level of expressionCostly and time-consume to developBioreactor/fermenter combinationsFungiDiseaseBipolar mood disorder
The invention concerns the genomic DNA, cDNA, and polypeptide sequences of CanIon, a novel voltage gated ion channel protein. The invention also concerns biallelic markers of the CanIon gene. The CanIon gene may be used as a biological target for the treatment and diagnosis of schizophrenia, bipolar disorder, and other diseases and conditions.
Owner:SERONO GENETICS INST SA

Methods for identifying modulators of N-type ion channel inactivation

InactiveUS7049094B2Potent anticonvulsantPotent neuroprotective propertyFungiBacteriaIon Channel ProteinNervous system
Methods and compositions for identifying compounds which disrupt the functional interaction of an intracellular receptor region of an α-subunit of a voltage-gated ion channel and an amino-terminal inactivation region of an ion channel protein are disclosed. Compounds that disrupt the functional or binding interaction of these two regions have significant modulatory effects on ion channel activity, and thus are likely to be useful for treating and / or preventing a wide variety of diseases and pathological conditions associated with ion channel dysfunction. Such conditions include, for example, neurological disorders, cardiac diseases, metabolic diseases, tumor-driven diseases, and autoimmune diseases.
Owner:WYETH LLC

Expression of voltage-gated ion channels in ciliates

Methods are disclosed for the production of mammalian voltage-gated ion channels in ciliates. In other aspects, compositions comprising lipid bilayers containing mammalian voltage-gated ion channels are disclosed. In other aspects, compositions comprising purified and reconstituted mammalian voltage-gated ion channels are disclosed.
Owner:ABCELLERA BOSTON INC

Mutations of voltage-gated ion channnels that allow them to express a voltage-independent phenotype and an improved method to use the same

The subject invention includes mutant voltage-gated ion channels that are open over a wide range of potential differences across membranes. The present invention also includes methods of use such mutant voltage-gated ion channels in cells with highly negative potential differences across their membranes. One preferred mutant voltage-gated ion channel is a channel with a mutation at the residue homologous to P513 in Kv1.5 and at least one mutation at one of the residues homologous to R400, R403, and R409 in Kv1.5.
Owner:CARDIOME PHARMA CORP

Methods for identifying modulators of N-type ion channel inactivation

Methods and compositions for identifying compounds which disrupt the functional interaction of an intracellular receptor region of an α-subunit of a voltage-gated ion channel and an amino-terminal inactivation region of an ion channel protein are disclosed. Compounds that disrupt the functional or binding interaction of these two regions have significant modulatory effects on ion channel activity, and thus are likely to be useful for treating and / or preventing a wide variety of diseases and pathological conditions associated with ion channel dysfunction. Such conditions include, for example, neurological disorders, cardiac diseases, metabolic diseases, tumor-driven diseases, and autoimmune diseases.
Owner:WYETH LLC

Methods for improved immunotherapy

Methods of adoptive Neurolmmunotherapy, selecting a subject suitable for adoptive Neurolmmunotherapy, selecting a molecule or combination of molecules for improving therapeutic immune cell potential, and decreasing PD-1 expression on a surface of an immune cell, comprising contacting immune cells with at least one molecule selected from a neurotransmitter or analog thereof, a neuropeptide or analog thereof, or a modulator of a voltage gated ion channel are provided. Kits comprising at least one of those molecules or comprising at least two of those molecules and optionally a PD-1 detecting agent are also provided.
Owner:LEVITE MIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products